BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Job Trends

  8 Companies Hiring Now in Regulatory

  Looking for a job in regulatory? Check out the BioSpace list of eight companies hiring life sciences professionals like you.

  October 23, 2025

   · 

  2 min read

   · 

  Angela Gabriel
• 

  Job Trends

  Posers and Pretenders: Interview Fraud Rising, Experts Say

  Biopharma professionals have become increasingly likely to be dishonest when interviewing for jobs, based on BioSpace interviews with three talent acquisition experts. The experts discuss the reasons why as well as the types of fraud happening, including people posing as applicants.

  October 23, 2025

   · 

  5 min read

   · 

  Angela Gabriel
• 

  Vaccines

  Moderna Scraps CMV Vaccine After Phase III Fail

  A key question for investors going forward will be whether Moderna’s other latent virus vaccines for Epstein-Barr and shingles can succeed after the failure of the CMV program.

  October 23, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Mergers & acquisitions

  Alkermes’ up to $2.1B Purchase of Avadel Sets Groundwork for ‘Strategic Evolution’

  With Avadel under its fold, Alkermes expects to accelerate its expansion into the sleep market, laying the foundation for its late-stage narcolepsy asset alixorexton.

  October 23, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Cystic fibrosis

  Arcturus Plunges on ‘Mixed’ Cystic Fibrosis Data for Inhaled mRNA Drug

  Despite showing no meaningful benefit on lung function, Arcturus’ mRNA therapy ARCT-032 reduced mucus volume in patients with cystic fibrosis—an outcome William Blair found “potentially promising.”

  October 23, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  MASH, Metsera Deals Send Analysts Marauding to Viking

  Viking Therapeutics CEO Brian Lian is watching the growth of interest in MASH and obesity but prepared to go it alone.

  October 23, 2025

   · 

  6 min read

   · 

  Annalee Armstrong
• 

  Earnings

  ‘We’re Not Done’: Roche Plans To Sustain Dealmaking Pace After 89bio

  Roche has already signed several high-ticket deals this year, including the $3.5 billion acquisition of 89bio and Genentech’s $2.1 billion molecular glue pact with Orionis Biosciences.

  October 23, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  IN PARTNERSHIP WITH ELEMENT

  How Supply Chain Turbulence Is Reshaping Biotech Strategy

  In this episode presented by Element Materials Technology, guests Dr. Jihye Jang-Lee and Dr. Khanh Courtney discuss how small biotechs face mounting pressure amid manufacturing uncertainties.

  October 23, 2025

   · 

  1 min read

   · 

  BioSpace Insights
• Press Releases

  Forlong Biotechology Announces Collaboration Agreement with Henlius to Develop Innovative Cancer Immunotherapy with an Engineered Cytokine

  October 23, 2025

   · 

  4 min read
• Press Releases

  Geneoscopy’s Scrape-Free Collection Method for Colorectal Cancer Screening Validated by New Data and Peer-Reviewed Publication

  October 23, 2025

   · 

  4 min read